Drug intelligence / Profile preview

TLC501

Development stage: Preclinical
Lead developer: Taiwan Liposome Company
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Not Specified, But Likely Local Injection Into Joint Space Based On Indication And Modality.

Overview

TLC501 is an investigational gene therapy for articular tissue regeneration, developed as a disease-modifying osteoarthritis drug (DMOAD). It utilizes RNA delivery via lipid nanoparticles (LNPs) to potentially prevent degeneration and stimulate regeneration of articular tissues. The goal is to not only alleviate pain but also modify the underlying disease progression in osteoarthritis patients[1].

Beyond the preview

Go deeper on TLC501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLC501.

Explore the full profile